Trials / Completed
CompletedNCT05419180
Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
Study of the Interest of the Combination of Stiripentol (Diacomit®) and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsies
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Biocodex · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (Diacomit®) and Carbamazepine.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Stiripentol | Since the treatment usually received by patients should not be modified, the sponsor will not intervene in any way in the therapeutic management of patients. |
Timeline
- Start date
- 2022-10-13
- Primary completion
- 2024-06-13
- Completion
- 2024-06-13
- First posted
- 2022-06-15
- Last updated
- 2024-07-24
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05419180. Inclusion in this directory is not an endorsement.